Crizanlizumab in Sickle Cell Disease

References

• Darbari DS , SheehanVA , BallasSK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. Eur. J. Haematol.105(3), 237–246 (2020).
   PubMed Web of Science ®Google Scholar
• Diallo D , TcherniaG. Sickle cell disease in Africa. Curr. Opin. Hematol.9(2), 111–116 (2002).
   PubMed Web of Science ®Google Scholar
• Aidoo M , TerlouwDJ , KolczakMSet al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet359(9314), 1311–1312 (2002).
   PubMed Web of Science ®Google Scholar
• CDC . Data & statistics on sickle cell disease. (2022). www.cdc.gov/ncbddd/sicklecell/data.htm
   Google Scholar
• Rizio AA , BhorM , LinXet al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual. Life Res.29(6), 1533–1547 (2020).
   PubMed Web of Science ®Google Scholar
• Cronin RM , HankinsJS , ByrdJet al. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology24(1), 189–198 (2019).
   PubMed Web of Science ®Google Scholar
• Powars DR , WeissJN , ChanLS , SchroederWA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?Blood63(4), 921–926 (1984).
   PubMed Web of Science ®Google Scholar
• Letvin NL , LinchDC , BeardsleyGP , McIntyreKW , MillerBA , NathanDG. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J. Clin. Invest.75(6), 1999–2005 (1985).
   PubMed Web of Science ®Google Scholar
• DeSimone J , HellerP , HallL , ZwiersD. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc. Natl Acad. Sci.79(14), 4428–4431 (1982).
   PubMed Web of Science ®Google Scholar
• Dover GJ , CharacheS , BoyerSH , VogelsangG , MoyerM. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood66(3), 527–532 (1985).
   PubMed Web of Science ®Google Scholar
• Charache S , TerrinML , MooreRDet al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med.332(20), 1317–1322 (1995).
   PubMed Web of Science ®Google Scholar
• Ault A . US FDA approves first drug for sickle-cell anaemia. Lancet351(9105), 809 (1998).
   PubMed Web of Science ®Google Scholar
• Brandow AM , LiemRI. Advances in the diagnosis and treatment of sickle cell disease. J. Hematol. Oncol.15(1), 20 (2022).
   PubMed Web of Science ®Google Scholar
• Niihara Y , MillerST , KanterJet al. A phase 3 trial of l-glutamine in sickle cell disease. N. Engl. J. Med.379(3), 226–235 (2018).
   PubMed Web of Science ®Google Scholar
• Shenoy S . Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther. Adv. Hematol.4(5), 335–344 (2013).
   PubMedGoogle Scholar
• Turhan A , WeissLA , MohandasN , CollerBS , FrenettePS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl Acad. Sci.99(5), 3047–3051 (2002).
   PubMed Web of Science ®Google Scholar
• Kutlar A , EmburySH. Cellular adhesion and the endothelium. Hematol. Oncol. Clin. North Am.28(2), 323–339 (2014).
   PubMed Web of Science ®Google Scholar
• Hebbel RP , OsarogiagbonR , KaulD. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation11(2), 129–151 (2004).
   PubMed Web of Science ®Google Scholar
• McEver RP . Selectins. Curr. Opin. Immunol.6(1), 75–84 (1994).
   PubMed Web of Science ®Google Scholar
• Wood K , RussellJ , HebbelRP , GrangeDN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation11(4), 377–385 (2004).
   PubMed Web of Science ®Google Scholar
• Embury SH . The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood104(10), 3378–3385 (2004).
   PubMed Web of Science ®Google Scholar
• Matsui NM , BorsigL , RosenSD , YaghmaiM , VarkiA , EmburySH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood98(6), 1955–1962 (2001).
   PubMed Web of Science ®Google Scholar
• Karki NR , KutlarA. P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: a spotlight on crizanlizumab. J. Pain Res.14, 849–856 (2021).
   PubMed Web of Science ®Google Scholar
• Barale C , RussoI. Influence of cardiometabolic risk factors on platelet function. Int. J. Mol. Sci.21(2), (2020). https://pubmed.ncbi.nlm.nih.gov/31963572/
   Web of Science ®Google Scholar
• Shen L , YangT , XiaKet al. P-selectin (CD62P) and soluble TREM-like transcript-1 (sTLT-1) are associated with coronary artery disease: a case control study. BMC Cardiovasc. Disord.20(1), (2020). https://pubmed.ncbi.nlm.nih.gov/32831023/
   Web of Science ®Google Scholar
• Hoel H , PettersenEM , HøisethLØet al. Effects of intermittent negative pressure treatment on circulating vascular biomarkers in patients with intermittent claudication. Vasc. Med.26(5), 489–496 (2021).
   PubMed Web of Science ®Google Scholar
• Song C , WuG , ChangS , BieL. Plasma P-selectin level is associated with severity of coronary heart disease in Chinese Han population. J. Int. Med. Res.48(6), (2020). https://pubmed.ncbi.nlm.nih.gov/32588673/
   Web of Science ®Google Scholar
• Hally KE , ParkerOM , Brunton-O’SullivanMM , HardingSA , LarsenPD. Linking neutrophil extracellular traps and platelet activation: a composite biomarker score for predicting outcomes after acute myocardial infarction. Thromb. Haemost.121(12), 1637–1649 (2021).
   PubMed Web of Science ®Google Scholar
• Eppihimer MJ , WolitzkyB , AndersonDC , LabowMA , GrangerDN. Heterogeneity of expression of E- and P-selectins in vivo. Circ. Res.79(3), 560–569 (1996).
   PubMed Web of Science ®Google Scholar
• Mayadas TN , JohnsonRC , RayburnH , HynesRO , WagnerDD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell74(3), 541–554 (1993).
   PubMed Web of Science ®Google Scholar
• Ghosh S , FlageB , WeidertF , Ofori-AcquahSF. P-selectin plays a role in haem-induced acute lung injury in sickle mice. Br. J. Haematol.186(2), 329–333 (2019).
   PubMed Web of Science ®Google Scholar
• Vats R , KaminskiTW , JuE-Met al. P-selectin deficiency promotes liver senescence in sickle cell disease mice. Blood137(19), 2676–2680 (2021).
   PubMed Web of Science ®Google Scholar
• Gutsaeva DR , ParkersonJB , YerigenahallySDet al. Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood117(2), 727–735 (2011).
   PubMed Web of Science ®Google Scholar
• Federici C , KucukalE , SertelSet al. Reduction in endothelial adhesion of red blood cells under crizanlizumab: assessment of standardized microfluidic platform in sickle cell disease population. Blood140(Suppl. 1), 11106–11107 (2022).
   Google Scholar
• US FDA . Crizanlizumab FDA prescribing information. (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
   Google Scholar
• Ataga KI , KutlarA , KanterJet al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N. Engl. J. Med.376(5), 429–439 (2017).
   PubMed Web of Science ®Google Scholar
• Kanter J , BrownC , NorrisCet al. Pharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease. Blood Adv.7(6), 943–952 (2023).
   PubMed Web of Science ®Google Scholar
• Wang W , WangE , BalthasarJ. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther.84(5), 548–558 (2008).
   PubMed Web of Science ®Google Scholar
• Saraf SL , AtagaKI , DerebailVKet al. A phase II, randomized, multicenter, open-label study evaluating the effect of crizanlizumab and standard of care (SoC) versus standard of care alone on renal function in patients with chronic kidney disease due to sickle cell nephropathy (STEADFAST). Blood138(Suppl. 1), 3096–3096 (2021).
   Google Scholar
• US FDA . FDA approves crizanlizumab-tmca for sickle cell disease. (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizanlizumab-tmca-sickle-cell-disease
   Google Scholar
• Kutlar A , KanterJ , LilesDKet al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am. J. Hematol.94(1), 55–61 (2019).
   PubMed Web of Science ®Google Scholar
• Ataga KI , KutlarA , DeBonnettL , LincyJ , KanterJ. Crizanlizumab treatment is associated with clinically significant reductions in hospitalization in patients with sickle cell disease: results from the SUSTAIN study. Blood134(Suppl. 1), 2289–2289 (2019).
   Google Scholar
• Liles DK , ShahNR , ScullinBet al. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br. J. Haematol.195(4), e150–e153 (2021).
   PubMed Web of Science ®Google Scholar
• Smith WR , AtagaKI , SarafSLet al. The effect of crizanlizumab on the number of days requiring opioid use for management of pain associated with vaso-occlusive crises in patients with sickle cell disease: results from the SUSTAIN trial. Blood136(Suppl. 1), 32–33 (2020).
   Google Scholar
• Liles D , Smith-WhitleyK , BrownRCet al. Pharmacokinetics/pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease and a history of vaso-occlusive crises: results from the phase II, multicenter, open-label SOLACE-adults study. Blood136(Suppl. 1), 17–19 (2020).
   Google Scholar
• Abboud MR , HowardJ , CançadoRet al. Crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, in adolescent and adult patients with sickle cell disease and vaso-occlusive crises: a randomized, double-blind, phase III Study (STAND). Blood134(Suppl. 1), 998–998 (2019).
   PubMedGoogle Scholar
• www.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab
   Google Scholar
• Anderson A , ElRassi F , DeBaunMRet al. Interim analysis of a phase 2 trial to assess the efficacy and safety of crizanlizumab in sickle cell disease patients with priapism (SPARTAN). Blood140(Suppl. 1), 1636–1638 (2022).
   Google Scholar
• ASH clinical news . Crizanlizumab-tmca becomes first approved targeted therapy for sickle cell disease.(2021).
   Google Scholar
• ClinicalTrials.gov . Study of crizanlizumab for prevention of silent cerebral infarcts in SCA (CRIZ). (2023). https://clinicaltrials.gov/ct2/show/NCT05334576
   Google Scholar
• Abboud M , KanterJ , MarfoKet al. Safety of crizanlizumab in patients with sickle cell disease: integrated post-marketing surveillance analysis. EHA Libr.387608, PB2512 (2023).
   Google Scholar
• Kanter J , ShahA , JoshiVet al. S108: a systematic post-marketing (PM) review of rare infusion-related reactions (IRRS) presenting as pain events during or after crizanlizumab infusion in patients with sickle cell disease (SCD). Hemasphere6, 4–5 (2022).
   Google Scholar
• Kanter J , ShahA , JoshiVet al. Rare cases of infusion-related reactions (IRRs) presenting as pain events during or after crizanlizumab infusion in patients (Pts) with sickle cell disease (SCD): a systematic evaluation of post-marketing (PM) reports. Blood138(Suppl. 1), 3112–3112 (2021).
   Google Scholar
• Terry M . FDA approves Novartis’ Adakveo for pain events associated with sickle cell disease. (2019). www.biospace.com/article/fda-approves-novartis-adakveo-for-sickle-cell-disease
   Google Scholar
• Pontinha V , AlmutairiM , HoldfordD. POSB156 cost-utility analysis of crizanlizumab and hydroxyurea in preventing vaso-occlusive events in patients with sickle-cell disease: a lifetime model from a payer’s and societal perspectives. Value Health25(1), S91 (2022).
   PubMed Web of Science ®Google Scholar
• Alashgar A , HoldfordD , PontinhaV. PRO51 cost-effectiveness of crizanlizumab compared to hydroxyurea for minimizing the frequency of vaso-occlusive (VOC) pain episodes in patients with sickle cell disease SCD from a payer perspective. Value Health23, S699 (2020).
   Web of Science ®Google Scholar
• ASH Clinical News webpage . ICER report finds that sickle cell drugs are too expensive. (2020). https://ashpublications.org/ashclinicalnews/news/4947/ICER-Report-Finds-That-Sickle-Cell-Drugs-Are-Too
   Google Scholar
• Spadaro S , FogagnoloA , CampoGet al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit. Care25(1), (2021). pmc/articles/PMC7894238/
   PubMed Web of Science ®Google Scholar
• Lopez-Castaneda S , García-LarragoitiN , Cano-MendezAet al. Inflammatory and prothrombotic biomarkers associated with the severity of COVID-19 infection. Clin. Appl. Thromb. Hemost.27, 1–9 (2021). pmc/articles/PMC8040552/
   Web of Science ®Google Scholar
• Venter C , BezuidenhoutJA , LaubscherGJet al. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int. J. Mol. Sci.21(21), 8234 (2020).
   PubMed Web of Science ®Google Scholar
• Fraser DD , PattersonEK , SlessarevMet al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit. Care Explor.2(9), e0194 (2020).
   PubMedGoogle Scholar
• Barrett TJ , LeeAH , XiaYet al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ. Res.127(7), 945–947 (2020).
   PubMed Web of Science ®Google Scholar
• Leucker TM , OsburnWO , ReventunPet al. Effect of crizanlizumab, a P-selectin inhibitor, in COVID-19: a placebo-controlled, randomized trial. JACC Basic Transl. Sci.6(12), 935 (2021).
   PubMedGoogle Scholar
• Connors JM , LevyJH. COVID-19 and its implications for thrombosis and anticoagulation. Blood135(23), 2033–2040 (2020).
   PubMed Web of Science ®Google Scholar
• Iba T , ConnorsJM , LevyJH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res.69(12), 1181 (2020).
   PubMed Web of Science ®Google Scholar
• Libby P , LüscherT. COVID-19 is, in the end, an endothelial disease. Eur. Heart J.41(32), 3038 (2020).
   PubMed Web of Science ®Google Scholar
• Lowenstein CJ , SolomonSD. Severe COVID-19 is a microvascular disease. Circulation142(17), 1609–1611 (2020).
   PubMed Web of Science ®Google Scholar
• Goshua G , PineAB , MeizlishMLet al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol.7(8), e575–e582 (2020).
   PubMed Web of Science ®Google Scholar
• Escher R , BreakeyN , LämmleB. Severe COVID-19 infection associated with endothelial activation. Thromb. Res.190, 62 (2020).
   PubMed Web of Science ®Google Scholar
• O’Sullivan JM , GonagleDM , WardSE , PrestonRJS , O’DonnellJS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol.7(8), e553 (2020).
   PubMed Web of Science ®Google Scholar
• Sakka M , ConnorsJM , HékimianGet al. Association between D-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. J. Med. Vasc.45(5), 268–274 (2020).
   PubMedGoogle Scholar
• Smilowitz NR , NguyV , AphinyanaphongsYet al. Multiple biomarker approach to risk stratification in COVID-19. Circulation143(13), 1338–1340 (2021).
   PubMed Web of Science ®Google Scholar
• Berger JS , KunichoffD , AdhikariSet al. Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. Arterioscler. Thromb. Vasc. Biol.40(10), 2539–2547 (2020).
   PubMed Web of Science ®Google Scholar
• Johnson ED , SchellJC , RodgersGM. The D-dimer assay. Am. J. Hematol.94(7), 833–839 (2019).
   PubMed Web of Science ®Google Scholar
• Olson JD . D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv. Clin. Chem.69, 1–46 (2015).
   PubMed Web of Science ®Google Scholar
• Leucker TM , OsburnWO , ReventunPet al. Effect of crizanlizumab, a P-selectin inhibitor, in COVID-19: a placebo-controlled, randomized trial. JACC Basic Transl. Sci.6(12), 935 (2021).
   PubMedGoogle Scholar
• American College of Clinical Pharmacology . FDA approves Adakveo for vasoocclusive crises in patients with sickle cell disease. (2019). https://accp1.org/Members/ACCP1/5Publications_and_News/FDA-Approves-ADAKVEO-Vasoocclusive-Crises-Sickle-Cell-Disease.aspx
   Google Scholar
• EMA . Adakveo. (2023). www.ema.europa.eu/en/medicines/human/referrals/adakveo
   Google Scholar
• Verachi P , MartelliF , ZingarielloMet al. Preclinical rationale for the use of crizanlizumab (SEG101) in myelofibrosis. Blood136(Suppl. 1), 26–27 (2020).
   Google Scholar
• ClinicalTrials.gov . Platform study of novel ruxolitinib combinations in myelofibrosis patients (ADORE). (2023). https://clinicaltrials.gov/ct2/show/NCT04097821
   Google Scholar
• Ault A . US FDA approves first drug for sickle-cell anaemia. Lancet351(9105), 809 (1998).
   PubMed Web of Science ®Google Scholar
• Brousseau DC , OwensPL , MossoAL , PanepintoJA , SteinerCA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA303(13), 1288–1294 (2010).
   PubMed Web of Science ®Google Scholar
• Brandow AM , LiemRI. Advances in the diagnosis and treatment of sickle cell disease. J. Hematol. Oncol.15(1), 1–13 (2022).
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute . A century of progress: milestones in sickle cell disease research and care. (2010). www.nhlbi.nih.gov/new/sicklecell.htm
   Google Scholar
• Eapen M , BrazauskasR , WaltersMCet al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol.6(11), e585–e596 (2019).
   PubMed Web of Science ®Google Scholar
• Kanter J , FalconC. Gene therapy for sickle cell disease: where we are now?Hematology2021(1), 174–180 (2021).
   PubMedGoogle Scholar
• ClinicalTrials.gov . Gene correction in autologous CD34+ hematopoietic stem cells (HbS to HbA) to treat severe sickle cell disease. (2023,). https://clinicaltrials.gov/ct2/show/NCT04819841
   Google Scholar
• Leonard A , TisdaleJF. A pause in gene therapy: reflecting on the unique challenges of sickle cell disease. Mol. Ther.29(4), 1355–1356 (2021).
   PubMedGoogle Scholar